Related Experiment Video

Updated: Aug 9, 2026

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method
16:07

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method

Published on: September 16, 2017

[Recent advances for research on anti-tumor effects of TNF-related apoptosis-inducing ligand]

Gen-Hong Yao1, Ya-Yi Hou

  • 1Department of Transfusion, Nanjing General Hospital of Nanjing Command, Nanjing 210002, China.

Wei Sheng Yan Jiu = Journal of Hygiene Research
|April 8, 2006
PubMed

Insights

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) triggers programmed cell death in many tumor cells but spares normal cells. This selective cancer cell killing ability makes TRAIL a promising therapeutic agent.

Area of Science:

  • Molecular biology
  • Immunology
  • Cancer research

Context:

  • Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a key member of the TNF superfamily.
  • TRAIL mediates programmed cell death (apoptosis) through specific receptor interactions.

Purpose:

  • To investigate the therapeutic potential of TRAIL in cancer treatment.
  • To understand the selective induction of apoptosis by TRAIL in tumor cells versus normal cells.

Summary:

  • TRAIL selectively induces apoptosis in a broad spectrum of cancer cells.
  • Most normal cells exhibit resistance to TRAIL-mediated apoptosis.
  • This selectivity is mediated by TRAIL's binding to its specific death receptors.

Impact:

  • TRAIL's ability to target tumor cells while sparing healthy tissues presents a significant advantage for cancer therapy.
  • The selective apoptotic effect of TRAIL has generated substantial interest in its development as a novel anti-cancer therapeutic agent.

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.